Niimoto M, Yoshinaka K, Hattori T, Kobayashi S, Hada Y, Hosoma S, Hatayama T, Ogawa Y, Iwamori S, Nagata N
Gan To Kagaku Ryoho. 1986 Feb;13(2):362-7.
A phase II study on THP((2''R)-4'-0-Tetrahydropyranyladriamycin) was performed in 47 patients with advanced or recurrent gastrointestinal cancer through the cooperation of nine institutions in Hiroshima Prefecture from April 1982 to November 1984. THP was given by means of intravenous infusion and/or intraaortic infusion and the 47 cases were divided into two groups according to the method of administration: (A) 40-60 mg/body every 3 or 4 weeks, or (B) 30 mg/body every week. Among 24 evaluable cases, partial response (PR) was observed in two cases of recurrent metastatic lymph nodes in gastric cancer patients. The (A) method of administration was more effective than (B). Subjective side effects observed were appetite loss, nausea, vomiting and general fatigue, but these were not so severe. Leukocyte nadir occurred at the 1st or 2nd week of THP administration, but thrombocytes were not appreciably decreased.
1982年4月至1984年11月期间，广岛县9家机构合作对47例晚期或复发性胃肠道癌患者进行了一项关于THP（(2''R)-4'-O-四氢吡喃阿霉素）的II期研究。THP通过静脉输注和/或主动脉内输注给药，47例患者根据给药方法分为两组：(A)每3或4周40 - 60 mg/体，或(B)每周30 mg/体。在24例可评估病例中，在胃癌复发性转移淋巴结患者中有2例观察到部分缓解（PR）。(A)给药方法比(B)更有效。观察到的主观副作用有食欲减退、恶心、呕吐和全身疲劳，但这些并不严重。白细胞最低点出现在THP给药的第1或第2周，但血小板没有明显减少。
